Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around Retinitis Pigmentosa and the unmet needs in its treatment.
The presentation entitled ‘Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)’ was presented at the Association for Research in Vision and Ophthalmology Annual Meeting, May 05-09, 2023
Questions:
- Could you tell us a little about Retinitis Pigmentosa and the unmet needs in its treatment? (0:19)
Disclosures: David Boyer has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual ARVO 2023.
Click here for more content on retinal diseases
Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA)
Transcript
My name is David Boyer. I’m a senior partner at Retina Vitreous Associates in Los Angeles, California, and an adjunct Clinical Professor at USC Keck school of medicine.
Could you tell us a little about Retinitis Pigmentosa and the unmet needs in its treatment?
Well, Retinitis Pigmentosa covers a large number of genetic diseases that affect both the rods and the cones and cause irreversible visual loss. Until now, there’s been very little in the way of potential treatments for these conditions. Until recently, optogenetics has allowed some of the patients who have very little to no vision, be able to have some visual acuity.
Subtitles and transcript are autogenerated
